Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Based on the latest data at ASCO26 awe can consider bispecifics especially teclistamab (has the most data) alone or in combination with daratumumab in first relapse of myeloma.
Here is our latest mSMART.org approach to first relapse.”
Other articles featuring Vincent Rajkumar on OncoDaily.